Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, November 5, 2020, at 5:00 p.m. ET to discuss a corporate update and results for the third quarter of 2020. Conference Call & Webcast Details Date:Thursday, November 5, 2020 Time:5:00 pm Eastern Time Toll Free:(844) 348-3801 International:(213) 358-0955 Conference ID:9992536 Webcast:https://...
Editas Medicine (NASDAQ: EDIT) shares experienced unusual options activity on Wednesday. The stock price moved down to $31.74 following the option alert. * Sentiment: BEARISH * Option Type: TRADE * Trade Type: CALL * Expiration Date: 2020-11-20 * Strike Price: $35.00 * Volume: 2009 * Open Interest: 7993Three Indications Of Unusual Options Activity Extraordinarily large volume (compared to historical averages) is one indication of unusual options market activity. Volume refers to the total...
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher
Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.
How far off is Editas Medicine, Inc. (NASDAQ:EDIT) from its intrinsic value? Using the most recent financial data...
This year’s Nobel Prize for chemistry was awarded to the two discoverers of Crispr/Cas9, which has led to gene-editing treatments for inherited illnesses like sickle-cell anemia.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance on March 25th after seeing unprecedented fiscal and monetary stimulus unleashed by the Fed and the Congress. […]
Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now?
Chris also chats with Motley Fool's Certified Financial Planner and Retirement Expert, Robert Brokamp. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. Chris Hill: We've got the latest headlines from Wall Street.